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Abstract
The targeted delivery of tumor necrosis factor-α (TNF-α) with antibodies specific to splice isoforms of fibronectin
[e.g., F8-TNF, specific to the extra-domain A (EDA) domain of fibronectin] has already shown efficacy against
experimental sarcomas but has not yet been investigated in orthotopic sarcomas. Here, we investigated F8-TNF in
a syngeneic K7 M2–derived orthotopic model of osteosarcoma as a treatment against pulmonary metastases, the
most frequent cause of osteosarcoma-related death. Immunofluorescence on human osteosarcoma tissue
confirmed the presence of EDA in primary tumors (PTs) as well as metastases. In mice, the efficacy of F8-TNF
against PTs and early pulmonary metastases was evaluated. Intratibial PT growth was not affected by F8-TNF, yet
early micrometastases were reduced possibly due to an F8-TNF–dependent attraction of pulmonary CD4+, CD8+,
and natural killer cells. Furthermore, immunofluorescence revealed stronger expression of EDA in early pulmonary
metastases compared with PT tissue. To study progressing pulmonary metastases, a hind limb amputation model
was established, and the efficacy of F8-TNF, alone or combined with doxorubicin, was investigated. Despite the
presence of EDA in metastases, no inhibition of progressive metastatic growth was detected. No significant
differences in numbers of CD4+ or CD8+ cells or F4/80+ and Ly6G+ myeloid-derived cells were observed,
although a strong association between metastatic growth and presence of pulmonary Ly6G+ myeloid-derived
cells was detected. In summary, these findings demonstrate the potential of F8-TNF in activating the immune
system and reducing early metastatic growth yet suggest a lack of efficacy of F8-TNF alone or combined with
doxorubicin against progressing osteosarcoma metastases.
Translational Oncology (2017) 10, 419–430
Introduction
Primary bone cancers, with osteosarcoma as its most common
representative, are among the deadliest cancers in children and
adolescents [1,2]. Following the introduction of chemotherapy in the
1970s, 5-year survival rates of osteosarcoma increased significantly
except for patients with metastatic disease, which remained at a low
20% until today [3]. Although the primary tumor (PT) can be
effectively treated using modern multidrug chemotherapy schemes
[i.e., doxorubicin (DOX), methotrexate, cisplatin] and surgery,
metastatic disease is inefficiently treated and thus remains to be the
strongest prognostic factor for poor patient survival [4].
To date, several studies demonstrated improved survival rates of
osteosarcoma patients after standard chemotherapy if hallmarks of an
activated immune system are present. For instance, postoperative
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infections in nonmetastatic osteosarcoma patients [5] as well as a
high ratio of intratumoral CD8+/FOXP3+ lymphocytes [6] were
found to be prognostic for improved survival rates of osteosarcoma
patients. In addition to improved survival rates, early recovery of
lymphocytes after neoadjuvant chemotherapy was indicative for
fewer relapses and was even observed to control metastatic disease
[7]. Similarly, a higher presurgical lymphocytes to monocytes ratio
was associated with better survival rates as well as a lower frequency
of metastases at diagnosis [8]. The addition of liposomal muramyl
tripeptide phosphatidylethanolamine, a stimulator of innate
immunity, to standard chemotherapy also demonstrated signifi-
cantly improved overall survival rates of osteosarcoma patients [9].
Taken together, these studies point to a survival benefit for
osteosarcoma patients mediated through a competent immune
system. Thus, it will be important to find out how to further
potentiate an effective anticancer immune response.
Already established cytotoxic chemotherapeutics such as anthra-
cyclines (e.g., DOX) can also induce immunogenic cell death [10].
To further enhance this chemotherapy-induced immune response,
a potent immunostimulatory cytokine can be employed. One of the
most potent proinflammatory cytokines is tumor necrosis factor–α
(TNF-α). Already around 1900, TNF-α contributed to impressive
antitumor effects against sarcomas and lymphomas [11,12]. The
antitumor effects of TNF-α depend on the tumor-bearing host
[13], especially its immune activating properties [14,15] or
destruction of the tumor vasculature [15,16]. However, systemic
use of TNF-α is limited through severe cytotoxic side effects
leading to shock, tissue injury, and even death, already observed at
TNF-α levels which can endogenously be produced by the host
[17]. To overcome limiting toxicities and to locally enhance
therapeut ic e f fec t s , var ious targe t ing moiet ie s (e .g . ,
NGR-containing peptides, or the F8, L19, TCP-1 antibodies)
have previously been coupled to TNF-α, with the aim of guiding it
to specific domains present in the tumor vasculature [18–21]. For
instance, TNF-α linked to the F8-moiety (F8-TNF), which targets
the extra-domain A (EDA) of fibronectin, was already demonstrat-
ed to have strong therapeutic efficacy against established subcuta-
neous (s.c.) soft tissue sarcomas [19]. Furthermore, locally
increased drug concentrations of F8-TNF may further enhance
its efficacy. In osteosarcoma patients, intratumoral concentrations
of standard chemotherapeutics (e.g., cisplatin) were elevated if the
drug was directly infused via the tumor feeding artery as compared
with standard intravenous (i.v.) administrations [22]. Recently, we
demonstrated that local intraarterial (i.a.) infusions of cisplatin
indeed led to superior tumor control [23].
In this study, we investigated the potential of F8-TNF to control
primary osteosarcoma growth as well as systemic spread and
metastatic disease. Using a clinically relevant syngeneic K7 M2–
derived orthotopic mouse model of osteosarcoma, drug efficacy was
first evaluated in early metastatic disease and in dependence of its
route of administration (i.e., i.a. versus i.v.). Because of the limited
time available for development of metastases, a hind limb amputation
model as previously described by Wolfe et al. was established [24].
This model allowed the development and monitoring of late
metastatic growth and was subsequently used to test the efficacy of
F8-TNF against progressing pulmonary metastases. Specifically, the
effects of F8-TNF, alone and combined with DOX, on the
circulating tumor cells (CTCs), pulmonary metastases, and cells of
the immune system were investigated.
Methods
Generation of the K7M2L2 Cell Line
Murine K7 M2 osteosarcoma cells (CRL-2836) were kindly
provided by Dr. Chand Khanna (Center for Cancer Research
National Institute, Bethesda, MD) and cultured in DMEM (4.5 g/l
glucose)/Ham F12 (1:1) medium (Invitrogen, Carlsbad, CA),
supplemented with 10% heat-inactivated fetal calf serum (FCS)
(GIBCO, Basel, Switzerland), at 37°C in a humidified atmosphere
containing 5% CO2. K7 M2 cells were transduced with a lacZ
reporter gene under control of a neomycin selection marker as
described [25]. Ten microliters of PBS/0.05% EDTA containing 1 ×
105 K7M2/lacZ cells were injected into the left tibia [intratibial (i.t.)]
of female, 8- to 10-week-old BALB/c mice as described before [25].
The K7M2L2/lacZ cell line was obtained after two rounds of in vivo
selection of pulmonary metastases–derived K7 M2 cells according to
Fidler's method [26]. Briefly, around 3 weeks after i.t. injection of K7
M2/lacZ cells, mice developed large PTs as well as pulmonary
metastases. During sacrifice, the lungs of the mice were collected, and
metastasized cells (K7M2L1/lacZ) were isolated by digestion of the
lung tissue using collagenase B (Roche, Mannheim, Germany) and
subsequently selected in cell culture medium containing 800 μg/ml of
G418 (Invitrogen, Life Technologies, Carlsbad, CA). The resulting
K7M2L1/lacZ cells were then reinjected (i.t.) into BALB/c mice to
obtain K7M2L2/lacZ cells in the same manner. After in vivo
selection, K7M2L2/lacZ cells were transduced with an mCherry-
containing plasmid (pQCIXH, containing a hygromycin selection
marker), which was kindly provided by Prof. Markus Rudin (Institute
of Biomedical Engineering, University and ETH Zurich, Zurich,
Switzerland). After transduction, K7M2L2/lacZ/mCherry cells were
selected in tissue culture medium with 1 mg/ml of G418 (Merck
Millipore) and 400 μg/ml of hygromycin (Merck Millipore) to stably
express lacZ and mCherry. A third round of transduction was
performed using a pQCIXP plasmid containing the luciferase2 gene.
The original plasmid was kindly provided by Dr. Geertje van der
Horst (Leiden University, Leiden, the Netherlands). Ultimately,
K7M2L2/lacZ/mCherry/luciferase2 cells (referred to as “K7M2L2”
throughout the manuscript) were selected using growth medium
supplemented with 1 mg/ml of G418, 400 μg/ml of hygromycin, and
1 μg/ml of puromycin (Invitrogen).
K7M2L2 Tumor Inductions
Female, 8-week-old BALB/c mice (BALB/cAnNCrl; Charles River
Laboratories, Sulzfeld, Germany) were maintained as described [23].
K7M2L2 cells were cultured below confluence, and 1 × 105 K7M2L2
cells were injected into left tibias as described [27]. Upon signs of
limping due to the tumor burden, 0.1 mg/kg of intraperitoneal (i.p.)
buprenorphine (Temgesic; Reckitt Benckiser, Berkshire, UK) was
given twice daily. Body weight measurements were performed weekly.
Animal care and experimental procedures were in accordance with the
institutional guidelines and approved by the Ethics Committee of the
Veterinary Department, Canton of Zurich, Switzerland (license
numbers 64/2013 and 160/2015).
Tumor Monitoring and Bone Measurements
After xenografting, tumor growth in the hind limbs of the mice was
monitored weekly using caliper measurements as described [28]. To
determine tumor load in the lungs or to detect remaining tumor cells
at the site of amputation, luciferase activity was measured. Mice were
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anesthetized using 5% isoflurane (Forane; AbbVie, Inc., North
Chicago, IL), and anesthesia was maintained with 2% isoflurane.
XenoLight D-luciferin was injected via the mouse tail vein following
the manufacturer's instructions (PerkinElmer, Waltham, MA).
Immediately after injection of the substrate, luciferase activity was
measured in an IVIS Lumina XR (Caliper Life Sciences, Inc.,
Hopkinton, MA) and quantified with Living Image v4.4 software
(Xenogen Corporation, Alameda, CA).
Micro–computed tomography (microCT) using a SkyScan1176
microCT system (Bruker, Billerica, MA) was performed as described
elsewhere [23]. Reconstituted images were segmented using CTAn
v1.13.11.0 (Bruker) to select regions of immature bone representing
malignant bone formation. Immature bone volumes were determined
in a region of interest starting from the distal end of the patella until
the convergence of tibia and fibula. Volumes were calculated using
the following formula: Δimmature bone volume [mm3] = bone
volumetumor-limb − bone volumehealthy-limb.
Amputations
Amputations were performed under 2% isoflurane anesthesia with
preoperative 0.1 mg/kg of i.p. buprenorphine, adapting the procedure
described by Wolfe et al. [24]. In brief, the hip region of the
tumor-bearing leg was shaved and disinfected with 70% ethanol. A
circumferential skin incision was made with small scissors at the plane of
the femur/proximal to the PT. After isolating the femoral artery, vein,
and nerve (see procedure described in [23]), the femoral artery and vein
were concurrently ligated with sterile silk sutures (Fine Science Tools
GmbH, Heidelberg, Germany) and cut proximal of the caudal femoral
artery. The circumferential musculature was transected distal to the level
of vessel ligation and separated from the femur. Using saw-toothed
scissors, the femur was then transected proximal to the knee joint at a
level which ensured complete macroscopic removal of the PT. Next, the
sciatic nerve was identified and transected, followed by the remainder of
the ischiocrural musculature to create a flap for subsequent closure. The
remaining musculature was used to cover the distal end of the transected
femur using 7-0 silk (Braun Melsungen, Melsungen, Germany). The
skin was closed using 7-0 silk in an intermittent pattern. After surgery,
the animals received 200μl of 0.9%NaCl i.p. to reestablish physiological
fluid levels. Analgesia using 0.1 mg/kg i.p. buprenorphine (Temgesic;
Reckitt Benckiser) was continued for 48 hours while closely monitoring
the animals, followed by carprofen (Rimadyl; Pfizer, New York, NY;
final concentration: 0.067mg/ml in the drinking water) given ad libitum
for 5 days [29]. Prior to any treatment study, amputations were first
applied in a “pilot amputation study” (See Supplementary methods).
Determination of Amount of Circulating Tumor Cells and
Pulmonary Metastases
At necropsy, whole mouse blood was obtained via cardiac
puncture. Three healthy, untreated female BALB/c mice served as
negative controls. Red blood cell lysis was performed using
ammonium-chloride-potassium lysis buffer, and the remaining cells
were divided into two parts. One part was briefly centrifuged at 1250
rpm for 3 minutes, dissolved in PBS, and stored at −20°C for the
analysis of genomic DNA, whereas the second part was immediately
analyzed using fluorescence-activated cell sorting (FACS). Genomic
DNA was isolated using a QIAmp DNA blood Mini Kit (Qiagen,
Hilden, Germany) following the manufacturer's instructions.
Tumor-specific mCherry-DNA and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH)-DNA were amplified using quantitative
polymerase chain reaction (PCR) (input: 10 ng of genomic DNA).
Primers were purchased from Microsynth (Balgach, Switzerland) and
used at 200 nM. Primer sequences are listed in Supplementary Table
S1. For quantitative PCR, amplification reactions were carried out
using Power SYBR Green PCR master mix (Applied Biosystems,
Foster City, CA) and the StepOne Plus Real-Time PCR system
(Applied Biosystems). Relative amounts of genomic mCherry were
determined using the 2−ΔΔCt method and normalized to the amount
of murine GAPDH.
FACS was performed to detect mCherry-positive circulating tumor
cells. Following red blood cell lysis of whole blood, cells were
suspended in PBS containing 0.5% FCS (Gibco by Thermo Fisher
Scientific, Waltham, MA). Fluorescent mCherry+ cells were counted
and normalized to the input volume of whole blood using a FACS
Aria III cellsorter (BD Biosciences, San Jose, CA). Postmortem, X-gal
staining of pulmonary metastases of the left lobes of the lung was
performed as described [28]. In addition, right lobes of frozen lung
were cross sectioned and hematoxylin and eosin stained. A
NanoZoomer-XR C12000 (Hamamatsu Photonics K.K., Japan)
was used to digitalize the sections, and analysis of metastatic areas was
performed using the corresponding NDP.view2 software.
Drug Infusions
The concentration of F8-TNF was adjusted using PBS [19]. Mice
anesthetized with 2% isoflurane were kept warm on a heating mat
throughout the procedure. Intravenous infusions were performed via the
tail vein using a 30G needle attached to a polyethylene catheter (Portex;
Smiths Medical, Inc., USA) under control of a syringe pump (Legato;
WPI, Inc., USA). Intraarterial infusions were performed similarly as
described [23].Mice received each treatment (PBS or 2μg of F8-TNF; i.v.
or i.a.) every 72 hours for a total of three times. In case of DOX, DOX
(5 mg/kg, i.v.; Sandoz, Holzkirchen, Germany) treatment was adminis-
tered once, as single agent or prior to the first infusion of F8-TNF (i.v.).
Experimental Design
In total, two treatment studies were performed: 1) “comparative
treatment study”: to compare infusions of i.v. and i.a. F8-TNF (or
vehicle = PBS) after establishement of a palpable PT (n ≥ 8 animals per
treatment group; 4 groups) and 2) “combination treatment study”: to
determine the effect of F8-TNF alone or in combination with DOX on
the growth of spontaneous pulmonary metastases and potential local
recurrences after amputation of the tumor-bearing hind limb [group
“vehicle”: n = 9; group “F8-TNF”: n = 9; group “DOX”: n = 8; group
“Comb” (combination; F8-TNF + DOX): n = 8]. Three mice did not
receive the planned doses and were excluded from all analyses.
Human Osteosarcoma Samples and Ethics Statement
The present study was approved by the local ethics committee (Ref.
Nr. EK10/2007), and written informed consent was obtained from
each subject or each subject's guardian. Primary human osteosarcoma
tissue was stored at −80°C and embedded in Tissue-Tek O.C.T.
(Sakura) for sectioning and immunofluorescence.
Immunohistology and Immunofluorescence
At necropsy and after cardiac puncture, mice were perfused with
PBS, and PTs and lungs were embedded in Tissue-Tek O.C.T.
Compound (Sakura Finetek, USA), frozen on dry ice, and cut (8-10
μm) in a CM3050S cryotome (Leica Biosystems, Newcastle, UK).
Frozen tissue sections were fixed in ice-cold acetone, blocked using
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20% FCS (Gibco by Thermo Fisher Scientific) in PBS, and stained.
Immunofluorescence was applied on frozen sections to detect EDA
(biotinylated F8; 1:100; as described [19]), CD4+ cells (rat anti-CD4,
GK1.5; BioXCell, West Lebanon, NH; 1:2000), CD8+ cells (rat
anti-CD8a, 2.43, BioXCell; 1:2000), natural killer (NK) cells (rabbit
anti-asialo GM1; Wako Pure Chemical Industries, Osaka, Japan;
1:3000), F4/80+ myeloid-derived cells (rat anti-F4/80, CI:A3–1,
BioXCell; 1:1000), and Ly6G+ myeloid-derived cells (rat anti-Ly6G,
1A8, BioXCell; 1:2000) using the respective primary antibodies/small
immunoproteins diluted in 0.2% BSA (Sigma-Aldrich, St. Louis,
MO). Each staining performed also included the respective isotype
controls [i.e., a small immunoprotein specific to hen-egg lysozyme
(1:150) or IgG2a (rat IgG2a, MAB006, R&D Systems, Minneapolis,
MN) or IgG2b (rat IgG2b, LTF-2, BioXCell; 1:2000)]. Primary
immunoproteins were detected with streptavidin-coupled Cy-3
(Sigma-Aldrich), goat anti-rabbit IgG-Alexa Fluor 647 (Life
Technologies by Thermo Fisher Scientific), goat anti-rabbit
IgG-Alexa Fluor 594 (Life Technologies), or goat anti-rat
IgG-Alexa Fluor 594 (Life Technologies). Stained slides were
mounted with fluorescent Shandon Immu-Mount (Thermo Fisher
Figure 1. EDA is expressed in various human osteosarcoma tissues. Representative examples of EDA expression (red) in a diagnostic
biopsy (before chemotherapy), resection (after chemotherapy), bone metastasis (BMet,) and lung metastasis (LMet). Nuclei were
counterstained with Hoechst (blue). EDA staining and merged (EDA and Hoechst) figures are shown separately. Scale bars correspond to
100 μm.
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Scientific); images were taken with an Axio Observer Z1 (Zeiss,
Oberkochen, Germany) and analyzed using ImageJ v1.47 (US
National Institutes of Health, Bethesda, MD).
Statistical Analysis
The results were given as mean ± standard error of the mean.
Means of end points were compared with one-way or two-way
analysis of variance (ANOVA) as indicated, and P values of the
one-way ANOVA or the column factors (corresponding to treatment,
i.e., vehicle versus F8-TNF) were stated in graphs, respectively. In
case the data were skewed (skewness N3 as determined by the g1
method), means were analyzed with a Kruskal-Wallis test. In case of
one-way ANOVA, Bonferroni posttests were performed to determine
statistical differences between individual groups, whereas a Dunn's
test was used for skewed data (significant differences were illustrated
in graphs). Mean values of time courses were compared with
repeated-measures two-way ANOVA unless stated otherwise (P
values of interactions were stated). Depending on the skewness of the
data, Pearson and Spearman correlations were performed. All
statistical tests were performed using Prism 5 v5.01 software
(GraphPad Software, Inc., La Jolla, CA) and were two-sided, and
P b .05 was regarded as statistically significant.
Results
EDA Expression in Human Osteosarcoma Tissue
Immunofluorescence against EDA on various samples of primary
human osteosarcoma demonstrated the presence of EDA. Briefly,
chemotherapy-naïve osteosarcomas (Figure 1; “biopsy”; 5 of 6 EDA+,
i.e., 83% of specimens) showed a generally more intense fluorescent
staining of EDA yet at a lower frequency compared with
chemotherapy-treated (“resection”; 5 of 5; 100%) samples. Metas-
tases present in lungs (“LMet”; 2 of 2; 100%) or bone metastases
(“BMet”; 2 of 2; 100%) were EDA positive but yielded weaker
staining intensities compared with primary tumors.
Comparative Treatment Study
Effects of F8-TNF Treatment on PT Growth. After confirming
the presence of EDA in human osteosarcoma, the effects of F8-TNF
against osteosarcoma were evaluated dependent on the route of
administration (i.a. versus i.v.) using the orthotopic K7M2L2
osteosarcoma model. After completing three treatments, no signifi-
cant differences in PT volumes were observed (Figure 2A). TNF-α
belongs to the class of osteoclastogenic cytokines [30]. To see if
F8-TNF treatment impacts bone remodeling, the formation of
Figure 2. F8-TNF (i.v. and i.a.) has no inhibitory effect on K7M2L2 PT growth yet reduces numbers of early pulmonary metastases. (A)
Tumor volumes determined by caliper (n ≥ 8). Days of drug infusion are indicated by black arrows. (B) Immature bone volumes as
determined by microCT scans prior to (pre) and after (post) treatment (n ≥ 8). Volumes of immature bone were analyzed both in control
limbs (CtrL) and in tumor-bearing limbs (TuL). Total number of superficial pulmonary metastases with (C) a diameter N0.5 mm and (D) a
diameter b0.5 mm, determined after X-gal staining (n≥ 5). (E) Representative sections demonstrate site-dependent EDA (red) expression
of K7M2L2 osteosarcoma cells. Nuclei were counterstained with Hoechst (blue). Scale bars correspond to 100 μm. (F) GenomicmCherry
normalized to GAPDH was analyzed using whole blood samples. Highest amount of mCherry was set as 100%, and relative values are
shown (n ≥ 6). RM-2way-ANOVA: repeated-measures two-way ANOVA.
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malignant bone tissue during tumor growth was quantified. An
increase in tumor-related immature bone production paralleling PT
volumes in the K7M2L2 model was observed (Pearson r = 0.43, P =
.007). As expected, no significant difference between immature bone
volumes was detected before any treatment (Figure 2B). Nevertheless,
after F8-TNF treatment, regardless of the route of administration, a
trend towards decreased volumes of immature bone deposited by the PTs
was detected (Figure 2B).
Furthermore, body weights of the mice were recorded to see if the
treatment itself impacts the general health of the mice. Throughout
the study, no significant differences were observed among the
different treatment groups (Supplementary Figure S1A). However,
because of the tumor growth, a progressing loss of body weight (up to
10% of the initial body weight) was observed. To exclude influences
on the downstream blood flow due to the different routes of drug
administration used, blood perfusion in the region of tumor growth
of the limb was monitored. After three rounds of i.a. or i.v. infusions,
no significant differences in perfusion of the region of PT growth
were detected (Supplementary Figure S1B).
Finally, to confirm the efficacy of the F8-TNF batch used in our
experiment, a setup similar to Mortara et al. [31] who demonstrated
efficacy of targeted TNF-α against s.c. transplants of K7 M2
osteosarcoma cells was used. Likewise, s.c. transplants of K7M2L2
cells responded to i.v. F8-TNFmarked by a reduction in tumor growth
and visible hemorrhagic necrosis (Supplementary Figure S2, A and B).
Interestingly, s.c. K7M2L2 transplants were marked by high levels of
EDA expression (Supplementary Figure S2C).
Reduction of Early Metastatic Growth by F8-TNF. In contrast to
the absence of effects of F8-TNF against the PT, a reduction in
systemic disease was observed after F8-TNF treatment. Interestingly,
dependent on the size of the pulmonary metastases, metastases were
differentially affected. Large macrometastases (diameter N0.5 mm;
Figure 2C) were not affected by either treatment or route of
administration, whereas F8-TNF significantly reduced the number of
micrometastases (diameter b0.5 mm; Figure 2D). At least in part, a
stronger expression of EDA by spontaneous pulmonary metastases
compared with the corresponding PT might explain the differential
effect of F8-TNF (Figure 2E).
To see if the reduction in early metastatic outgrowth was also
linked to a treatment-dependent reduction in CTCs, the amount of
genomic mCherry DNA was determined using the cellular fraction of
blood samples and qPCR analysis. Treatment with F8-TNF showed a
trend towards reduced numbers of CTCs (Figure 2F). In addition to
qPCR, the amount of CTCs after i.a. F8-TNF was determined using
FACS in selected mice. Mice treated with i.a. F8-TNF had reduced
numbers of mCherry+ tumor cells within the blood circulation
Figure 3. Treatment with F8-TNF increases infiltration of immune cells in the lung. (A) Representative examples of immunofluorescence
analysis of CD4+ T cells in the lungs of mice from each treatment group (from top to bottom: i.v. vehicle; i.v. F8-TNF; i.a. vehicle; i.a.
F8-TNF). (B) Total numbers of CD4+ (n≥ 4), CD8+ [(C), n≥ 4], and NK cells [(D), n≥ 3] determined in 5 high-power fields (HPF) from lungs
of individual mice.
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(Supplementary Figure S3). Thus, despite a lack of significant
reduction of PT growth, early metastatic disease was affected.
Activation of Immune Cells in the Lung Parenchyma by F8-
TNF. Given the role of the immune system in controlling tumor
progression, numbers of CD4+ or CD8+ cells and NK cells in the
lung parenchyma were quantified using immunofluorescence (e.g.,
example of CD4+ cells in the lungs depicted in Figure 3A).
Significantly increased numbers of CD4+ cells (Figure 3B) as well as
CD8+ cells (Figure 3C) in the lung parenchyma were observed after
F8-TNF treatment. In case of NK cells (Figure 3D), increased
numbers were observed after F8-TNF treatment; however, i.a. drug
administrations showed a larger increase compared with i.v.
administrations.
Combination Treatment Study
F8-TNF Treatment and Progression of Metastases. Next, we
tested the efficacy of F8-TNF against late pulmonary metastases in
our K7M2L2 model. To this end, a hind limb amputation model was
established and characterized. Using this model, we detected a fast
recovery of the animals after amputation (Supplementary Figure S4A)
and found a correlation between increasing numbers of pulmonary
metastases and continuous PT growth (Pearson r = 0.894;
Supplementary Figure S4B). Metastatic growth was followed over
Figure 4. F8-TNF and DOX do not inhibit late metastatic osteosarcoma. (A) CTCs analyzed using FACS of mCherry+ tumor cells detected
in whole blood (n ≥ 8). Quantification of lacZ+ (B) micrometastases (diameter b0.5 mm) and (C) macrometastases (diameter N0.5 mm)
detected on the surface of the left lobe of the lung after X-gal staining postmortem (n ≥ 8). (D) Total area of pulmonary metastases as
determined by histological evaluation of lung cross sections (n≥ 5). (E) in vivomonitoring of luciferase+ tumor cells in the thoracic region
by measuring luminescent flux (n ≥ 8). Black arrowheads indicate administration of treatment. RM-2way-ANOVA: repeated-measures
two-way ANOVA; d: days; amp: amputation.
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time (e.g., metastatic growth patterns, Supplementary Figure S4C
and Supplementary Table S2), yet only amputation of large PT
resulted in progression of pulmonary metastases (Supplementary
Figure S4D). Furthermore, the presence of EDA in progressed
metastases was confirmed (Supplementary Figure S4E). Moreover,
intraabdominal soft tissue recurrences were detected in 33% to 38%
of animals which have received limb amputation of a large PT (data
not shown).
As shown by Hemmerle et al., DOX, a standard drug also used in
osteosarcoma chemotherapy, was shown to potentiate the antitumor
effect of F8-TNF [19]. Therefore, we combined the use of DOX and
F8-TNF to evaluate the individual and combined efficacies against
systemic disease in the context of our amputation model. Similar to the
“comparative treatment study,” the number of CTCs was evaluated
using FACS of mCherry+ tumor cells. However, no significant
differences in mean numbers of CTCs were observed (Figure 4A).
Mice treated with vehicle (range: 0-34 mCherry+ cells/ml) or DOX
(0-11) only showed the highest maximum number of CTCs compared
with F8-TNF–treated (0–5) or Comb-treated (0–2) animals.
Neither the absolute numbers of X-gal + micrometastases
(Figure 4B) nor macrometastases (Figure 4C) were significantly
affected. Throughout the study, in vivo luciferase activity measure-
ments were performed which demonstrated similar progressive
growth of late pulmonary metastases in all treatment groups
(Figure 4D). To validate the in vivo measurements, histological
determination of metastatic areas in lung cross sections was performed
without detecting differences between treatments (Figure 4E).
However, a significant correlation between luciferase activity in the
thoracic region and the histological analysis of total metastatic lung
areas was detected (Pearson r = 0.78; P b .0001). Despite lacking
statistical significance, we noticed that the combination treatment
indicated the lowest metastatic loads as well as a delay of metastatic
growth until the end of the treatment (Figure 4D; = “9 d post amp”).
In general, all tested treatment regimens were well tolerated without
causing a severe loss of body weight (Supplementary Figure S5).
Effects of F8-TNF Treatment on Spleen Size and Numbers of
Leukocytes. Enlarged spleens were observed in several immunocom-
petent mouse models of cancer and were associated with enhanced
Figure 5. Late metastatic growth associates with pulmonary Ly6G+ myeloid-derived cells. (A) Lengths of spleens were measured ex vivo
after sacrifice of the mice (n ≥ 8). (B) Numbers of CD4+ and (C) CD8+ cells as well as (D) F4/80+ myeloid-derived cells in the lungs
determined in 5 HPF from lungs of individual mice (n≥ 5). (E) Ly6G+ area normalized to the Hoechst+ area in nonmetastatic areas of the
lung. Association curve showing a correlation between number of Ly6G+ myeloid-derived cells in the lung parenchyma and growth of
luciferase+ pulmonary metastases (n = 21).
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metastasis or increased granulocytosis [32–34]. Speculating that
F8-TNF treatment might also influence the composition of
lymphocytes or granulocytes in our osteosarcoma model, the lengths
of spleens were measured. Significantly enlarged spleens were
observed after F8-TNF treatment compared with vehicle- or
DOX-treated mice (Figure 5A). The mean length of spleens of
Comb-treated mice was shorter than spleens of F8-TNF–treated
mice, without reaching significance. In contrast, the spleen size was
not altered after F8-TNF treatment during the “comparative
treatment study” (data not shown). Similar to the “comparative
treatment” study, we again investigated the immune infiltrate of
the lungs. No significant differences between numbers of CD4+
(Figure 5B) or CD8+ cells (Figure 5C), F4/80+ myeloid-derived
cells, or areas of Ly6G+ myeloid-derived cells (Figure 5D) in the lung
parenchyma were identified. Nevertheless, treatment with F8-TNF
tended to increase the mean number of Ly6G+ myeloid-derived cells
in the lung parenchyma (15.24 ± 3.96%; percent Ly6G+
myeloid-derived cells ± standard error of the mean) especially if
compared with vehicle (4.62 ± 1.66%) but also with DOX (14.99 ±
7.52%) and Comb (9.79 ± 4.66%). In addition, the transition from
early (i.e., at the time of amputation) until progressive metastatic
growth was closely associated with a stable and significant increase of
Ly6G+ myeloid-derived cells in the lung parenchyma irrespective of
treatment (Figure 5E and Supplementary Figure S6). None of the
other immune cells analyzed yielded a similar association (data not
shown).
Discussion
In this study, we investigated the effects of targeted TNF-α in early
and late stages of osteosarcoma development. We showed that
F8-TNF reduced establishment of early micrometastases of osteosar-
coma but was not able to significantly prevent the growth of
progressing pulmonary metastases. In addition, we demonstrated that
the overall efficacy of F8-TNF treatment was largely independent on
the route of drug administration (i.a. versus i.v.).
We and others detected the presence of EDA in primary human
osteosarcoma tissues, rendering it a potential target for future
therapeutic approaches against osteosarcoma [35]. Our results
showed a differential expression of EDA in the K7M2L2
osteosarcoma model dependent on the site of tumor growth. Low
expression of EDA was observed in orthotopic i.t. PTs, whereas
pulmonary metastases derived from their corresponding PT were
characterized by stronger EDA expression. Furthermore, s.c.
K7M2L2 osteosarcoma transplants were characterized by increased
EDA expression compared with i.t. PTs. In addition, F8-TNF
treatment of s.c. K7M2L2 transplants resulted in measureable
antitumor effects, confirming previously published data [31]. These
findings highlight the importance of EDA expression by the target;
however, we cannot exclude the possibility that the EDA expression
changes with tumor size/stage (e.g., small tumors/metastases might
possess higher expression of EDA). Furthermore, reduced efficacy of
F8-TNF against i.t. PTs might also be due to the tumor
microenvironment (i.e., s.c./skin versus i.t./bone). For instance, the
trend in reduced immature bone volume observed after F8-TNF
treatment might demonstrate a treatment effect in the vicinity of the
tumor (i.e., increased osteoclastogenesis due to local TNF-α [30]),
which affects bone remodeling rather than tumor growth. In addition,
it is more and more accepted that cells of the bone microenvironment
and immune cells are interconnected by a complex cross talk of
signaling molecules such as inflammatory cytokines [36]. Neverthe-
less, further studies are required to fully explain the differences in PT
responses after F8-TNF treatment.
It is widely accepted that the establishment of metastasis is a highly
selective process. Thus, only a small set of specialized tumor cells is
capable of intravasation and distant organ colonization [37],
dependent on the expression of specific surface molecules [38–40].
To study the efficacy of an immunomodulatory drug such as
F8-TNF, a model recapitulating the establishment of naturally/
immune-selected pulmonary metastases is critical. The here presented
study used an immunocompetent K7 M2–derived model system
which was already considered as being clinically relevant [41].
Through further manipulation of the original K7 M2 cell line, our
K7M2L2 model effectively mimicked the different stages of human
osteosarcoma progression (i.e., CTCs, development of pulmonary
metastases) while at the same time permitting quantitative measure-
ments of each stage. As a limiting factor, the presence of a too large PT
is considered as a dropout criterion by our animal welfare agency.
Thus, the PT was removed through amputation of the tumor-bearing
limb, not only providing longer study times of pulmonary metastases
but also being a better representation of clinical progressive metastatic
osteosarcoma, where the PT is most frequently removed. In
summary, the here described models of spontaneous osteosarcoma
metastases allowed the proper assessment of a drug's therapeutic value
against metastatic disease [42].
In the “comparative treatment study,” a reduction of micrometa-
static disease and, thus, action of F8-TNF against early pulmonary
metastatic seeds were demonstrated. Recently, other studies demon-
strated altered levels of immune cells which were linked to success of
therapy against osteosarcoma. For instance, an increase in CD8+ T
cells [43] or increases in NK cells [44,45] seemed to be mediators of
successful immunotherapy against osteosarcoma and metastases
thereof. Likewise, our study demonstrated an increase of CD4+,
CD8+, and NK cells in the lung parenchyma after F8-TNF
treatment, which may provide an explanation for the reduced
numbers of early pulmonary metastases. Especially in the case of i.a.
F8-TNF, higher numbers of NK cells in the lung parenchyma were
observed, while, at the same time, early micrometastatic seeds were
removed more efficiently. In line with our findings, the observation of
enhanced removal of early intraluminal metastatic seeds by NK cells
in the lung parenchyma [46] might partially explain the efficacy of
F8-TNF against early pulmonary metastases. However, further
studies will be required to decipher the precise mechanisms of
control of early metastatic disease by F8-TNF treatment.
Despite the advantages of studying osteosarcoma in the presence of
a PT, a model allowing prolonged study times was required to
investigate progressive metastatic disease. Using an amputation
model, we demonstrated that progressing pulmonary metastases
were not affected by F8-TNF treatment. Even the addition of DOX
to F8-TNF only slightly delayed further growth of established
metastases. Interestingly, enlarged spleens were observed after
F8-TNF therapy yet only in the case of progressive metastatic
disease. As demonstrated by others using fibrosarcoma or breast
cancer models, enlarged spleens were correlated with increased
numbers of myeloid-derived suppressor cells (i.e., monocytes and
granulocytes) in general [47] or neutrophils [48], both of which are
indicative for an immunosuppressive environment [49]. For instance,
production of arginase I by myeloid-derived suppressor cells is
considered to be a main mechanism of T cell suppression [50]. In line
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with these findings, our study revealed a strong relationship between
pulmonary metastatic growth and an increase of Ly6G+
myeloid-derived cells in the lung parenchyma. These observations
may suggest the presence of mechanisms invoked by Ly6G+
myeloid-derived cells helping metastasized tumor cells to successfully
evade the immune system and continue metastatic outgrowth [51].
Our study showed that targeting of pulmonary metastasis using
F8-TNF in osteosarcoma is feasible to reduce early metastatic disease.
In contrast, other in vivo studies using osteosarcoma cell lines
demonstrated an increased metastatic burden if osteosarcoma cells
were treated with TNF-α prior to injection [52], whereas the
spontaneous metastatic load in an orthotopic model was reduced
upon administration of a TNF-α–blocking antibody [53]. These
contradicting results might be explained by the use of immunocom-
promised mice in these studies, where the study of the adaptive
immune system was compromised. To our knowledge, no other
preclinical studies have assessed the direct effects of targeted TNF-α
therapy against osteosarcoma progression so far. In support of our
study and TNF-α as a potent anticancer agent, local delivery of
TNF-α in immunocompetent models of breast, skin, and lung cancer
as well as sarcomas demonstrated strong growth inhibition of PTs
[19] and even metastases [54]. However, in contrast to our study, the
effects of local delivery of TNF-α on late, spontaneous metastatic
growth were not assessed by Dondossola et al. The failure of F8-TNF
in reducing progressive metastatic osteosarcoma in our study might be
partially explained by a simultaneous increase of Ly6G+
myeloid-derived cells with increasing metastatic burden, similar to
what was demonstrated in models of mesothelioma and Lewis lung
carcinoma [55]. Here, the targeted delivery of TNF-α to metastatic
nodules in the lungs might have provoked an inflammatory reaction
which recruited Ly6G+ myeloid-derived cells as the first leukocytes
[56]. Likewise, by studying a model of peritonitis, a strong influx of
Ly6G+ myeloid-derived cells was observed after local injection of
TNF-α [57].
In conclusion, the present study demonstrated efficacy of neoadju-
vant F8-TNF against early metastatic disease with minor importance of
the route of administration. However, treatment efficacy of F8-TNF
against progressive metastatic osteosarcoma was abrogated, seemingly
by the presence of an immunosuppressive environment. Taken
together, the here presented clinically relevant models of osteosarcoma
can be used in future studies to evaluate therapeutic approaches against
multiple stages of metastatic osteosarcoma as well as to assess
EDA-targeted cytokine delivery to pulmonary metastases.
Appendix A. Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2017.02.005.
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